We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Icelandic Program Aims to Eliminate Hepatitis C

Icelandic Program Aims to Eliminate Hepatitis C content piece image
Credit: Centres for Disease Control and Prevention.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

A new Journal of Internal Medicine study describes an innovative program to eliminate hepatitis C virus (HCV) as a public health threat in Iceland.

In the TraP Hep C program, which started in January 2016, an emphasis is placed on finding early cases and treating patients at high risk for transmitting HCV: people who inject drugs. All patients with national health insurance are offered treatment regardless of fibrosis stage and comorbid conditions. 

The program includes a multidisciplinary public health model of care and cooperation between government, health services, the penitentiary system, and community organizations. The results of the Icelandic project will provide important data and inform others globally trying to achieve the World Health Organization’s goal of HCV elimination by 2030.

"So far this project has been extremely well received by patients, and we are aiming to complete the active treatment phase, encompassing all known cases in the country, by the end of 2018,” said senior author Dr. Magnus Gottfredsson, of the University of Iceland.

This article has been republished from materials provided by Wiley. Note: material may have been edited for length and content. For further information, please contact the cited source.

Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct-acting antiviral agents. S. Olafsson, T. Tyrfingsson, V. Runarsdottir, O. M. Bergmann, I. Hansdottir, E. S. Björnsson, B. Johannsson, B. Sigurdardottir, R. H. Fridriksdottir, A. Löve, M. Hellard, T. J. Löve, T. Gudnason, M. Heimisdottir, M. Gottfredsson.  Journal of Internal Medicine, 7 March 2018, DOI: 10.1111/joim.12740.